Medidata SCA Wins Scrip Award for Best Technological Development in Clinical Trials - Sponsor Focused
December 06 2017 - 8:30AM
Business Wire
Medidata (NASDAQ:MDSO), the leading global provider of
cloud-based technology and data analytics for clinical research, is
pleased to announce that the Medidata Synthetic Control Arm (SCA)
was recognized at the 2017 Scrip Awards as the "Best Technological
Development in Clinical Trials - Sponsor Focused." Out of the 15
other award categories, 11 of the nominees are Medidata
customers.
The first-of-its-kind scientific offering, Synthetic Control Arm
(SCA), leverages Medidata Enterprise Data Store (MEDS) clinical
data repository that includes thousands of oncology trials. It
forms a control arm made up of patients with baseline disease and
demographic characteristics that match the experimentally treated
patients in a current-day single arm trial. SCA enables safety,
efficacy and subgroup analyses of a single arm trial that are usual
for a concurrently controlled trial.
“The Scrip Awards judges selected the Medidata Synthetic Control
Arm as the best sponsor-focused technological development in
clinical trials because eliminating an entire control arm of a
trial with a powerful improvement to historical controls is truly
innovative, offering both cost and time savings as well as reducing
the burden on their entire clinical trial ecosystem,” noted Mike
Ward, global head of content for Informa Pharma Insights
portfolio.
Presented to Medidata at the 13th Annual Scrip Awards on
November 29, 2017 in London, the award celebrates excellence and
innovation in the biopharmaceutical industry and a continued
commitment to improving healthcare on a global scale. A panel of
judges—comprised of independent, senior industry experts from
around the world—evaluated a record number of submissions across a
wide range of categories, announcing a shortlist of finalists
earlier this year. The Scrip Awards are managed by Scrip
Intelligence, the premier source of information for the
pharmaceutical industry.
“We are delighted to see that the Roche and Medidata
collaboration on Synthetic Control Arm Development received the
Scrip Award. These data, which were presented at the 2017 ASCO
annual meeting, share our commitment to our scientists and research
partners to help advance our oncology disease area understandings,”
said Somnath Sarkar, PhD, senior director and therapeutic area
global head for hematology-oncology and pRED oncology biostatistics
at Roche.
“SCA utilizes patient-level historical clinical trial data to
enhance the interpretation of single arm trials, making predictions
about the treatment effect sizes of experimental products likely to
be observed in confirmatory concurrently controlled trials long
before they are conducted,” said David Lee, chief data officer,
Medidata. "With the Medidata Synthetic Control Arm, we have enabled
our clients’ important go/no-go decisions to be made with more
accuracy and certainty, which translates into improved ROI for
their R&D investments.”
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
over 950 global pharmaceutical companies, biotech, diagnostic and
device firms, leading academic medical centers, and contract
research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 18 of the top
25 medical device developers—from study design and planning through
execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171206005243/en/
Medidata SolutionsInvestor:Betsy Frank,
917-522-4620bfrank@mdsol.comorAnthony D’Amico,
732-767-4331adamico@mdsol.comorMedia:Erik Snider,
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Sep 2023 to Sep 2024